

A randomised, double blind, placebo controlled, crossover trial of the adjuvant properties of imipramine for the overactive bladder

Submission date 13/02/2008	Recruitment status No longer recruiting	☒ Prospectively registered
		☐ Protocol
Registration date 20/02/2008	Overall study status Completed	☐ Statistical analysis plan
		☐ Results
Last Edited 06/06/2016	Condition category Urological and Genital Diseases	☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof James Malone Lee

Contact details

Department of Medicine
University College London
Clerkenwell Building
Highgate Hill
Archway
London
United Kingdom
N19 5LW
+44 (0)207 2885301
james.malone-lee@ucl.ac.uk

Additional identifiers

Protocol serial number

PB-PG-0107-12198

Study information

Scientific Title

A randomised, double blind, placebo controlled, crossover trial of the adjuvant properties of imipramine for the overactive bladder

Study objectives

We hypothesise that 25 mg imipramine in addition to antimuscarinic drugs is superior to placebo in addition to an antimuscarinic drug for the treatment of overactive bladder symptoms.

Ethics approval required

Old ethics approval format

Ethics approval(s)

An application to the Moorfields and Whittington Research Ethics Committee is in progress as of 13/02/2008 – approval pending

Primary study design

Interventional

Study design

Randomised double-blind placebo-controlled cross-over trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Overactive bladder symptoms

Interventions

Imipramine 25 mg once a day given orally vs placebo.

Imipramine will be given for 6 weeks followed by placebo for 6 weeks and vice versa in the other arm of this cross-over trial.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Imipramine

Primary outcome(s)

Urgency score questionnaire (Al Buheissi S, et al., 2008), carried out after 1 week of run-in period and at 2, 4, 6, 8, 10 and 12 weeks.

Key secondary outcome(s)

The following will be assessed after 1 week of run-in period and at 6 and 12 weeks:

1. 24 hour urinary frequency
2. Daily urinary Incontinence records

3. Patient preference for treatment
4. Incontinence Quality of Life questionnaire (I-QOL) score
5. Record of side effects

Completion date

01/05/2010

Eligibility

Key inclusion criteria

1. Age $\geq$ 18 years
2. Able to consent
3. Suffering from overactive bladder symptoms
4. Taking antimuscarinic treatment for detrusor overactivity

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Unable to consent
2. Pregnant
3. Breast feeding
4. Recent myocardial infarction
5. History of psychiatric illness
6. Taking monoamine oxidase inhibitors
7. <18 years

Date of first enrolment

01/05/2008

Date of final enrolment

01/05/2010

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
University College London
London
United Kingdom
N19 5LW

Sponsor information

Organisation
The Whittington Hospital NHS Trust (UK)

ROR
<https://ror.org/01ckbq028>

Funder(s)

Funder type
Government

Funder Name
National Institute for Health Research - the Research for Patient Benefit (RfPB) programme (ref: PB-PG-0107-12198)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration